
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
4 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
12 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
26 | -0.781 | -79.6126401631 | 0.981 | 1.022 | 0.121 | 171724 | 0.46057074 | CS |
52 | -1.56 | -88.6363636364 | 1.76 | 3.39 | 0.121 | 954862 | 1.28014885 | CS |
156 | -87.8 | -99.7727272727 | 88 | 88.47 | 0.121 | 804554 | 6.45029788 | CS |
260 | -103.6 | -99.8073217726 | 103.8 | 486.8 | 0.121 | 747569 | 58.61070046 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions